アプタマー アフェレシス 核酸医薬の開発|タグシクス・バイオ株式会社

R&D Products

In house pipeline

Tagcyx biotechnologies inc. is promoting its business with a focus on drug discovery through its platform technology, "Xenoligo®", that enables the creation of highly functional single-strand DNA aptamer from DNA libraries containing artificial bases and the stabilization of nucleic acid molecules using mini-hairpin technology.
The basic technology of artificial nucleic acid base, which is the proprietary technology of Tagcyx Biotechnologies, was developed by a research team led by Ichiro Hirao (currently at Xenolis, Singapore). Tagcyx Biotechnologies was then established as a biotech company spined out from RIKEN institute in March 2007, with the aim of commercializing this technology in a wide range of fields.